Publication | Closed Access
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
79
Citations
0
References
2011
Year
Surgical OncologyCancer ManagementImmunologyPathologyAnnual Meeting ProceedingsTumor BiologyClinical TrialsClinical OncologyRandomized TrialAdjuvant ImatinibRadiation OncologyCancer ResearchFinal TextHealth SciencesHigh RiskMedicineCancer TreatmentMalignant DiseaseOncology
LBA1 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.